Abstract Objective To study the dynamic changes in Th17 cells and CD4+ CD25+ regulatory T cells (Treg) in the spleen and to analyze their relationship with airway remodeling.Methods A total of 48 female specific pathogenfree Balb/c mice were randomly divided into control and asthmatic groups. To establish the asthmatic airway remodeling model, the mice were sensitized to ovalbumin (OVA) through intraperitoneal injection of OVA and aluminum hydroxide suspension and challenged by inhalation of aerosol OVA. The matched control group was treated with normal saline instead. In 24 hours after 2-week, 4-week, and 8-week aerosol inhalation, 8 mice were randomly selected from each group and sacrificed. Then histopathological examination of the left lung was performed to measure the degree of airway remodeling. The percentages of Th17 and CD4+ CD25+ Treg cells in total CD4+ cells from the spleen were determined by flow cytometry.Results In the asthmatic group, the ratios of total bronchial wall area to bronchial basement membrane perimeter (WAt/Pbm) and bronchial smooth muscle area to bronchial basement membrane perimeter (WAm/Pbm) significantly increased as the challenge proceeds (PP+ CD25+ Treg cells from the suspension gradually decreased and it was negatively correlated with the degree of asthmatic airway remodeling (PConclusions In mice with asthma, as the challenge proceeds, the airway remodeling becomes more severe, the percentage of Th17 cells increases, and the percentage of CD4+ CD25+ Treg cells decreases. The immunological imbalance is possibly one of the important factors inducing airway remodeling.
LOU Chun-Yan,LI Min,LI Li. Dynamic changes in percentages of CD4+ CD25+ regulatory T cells and Th17 cells in process of airway remodeling in mouse model of asthma[J]. CJCP, 2015, 17(9): 994-1000.
LOU Chun-Yan,LI Min,LI Li. Dynamic changes in percentages of CD4+ CD25+ regulatory T cells and Th17 cells in process of airway remodeling in mouse model of asthma[J]. CJCP, 2015, 17(9): 994-1000.
Bergeron C, Al-Ramli W, Hamid Q. Remodeling in asthma[J]. Proc Am Thorac Soc, 2009, 6(3):301-305.
[6]
Valentin ED, Crahay C, GarbackiN, et al. New asthma biomarkers:lessons from murine models of acute and chronic asthma[J]. Physiol Lung Cell M olPhysiol, 2009, 296(2):185-197.
[7]
Kay AB. Allergy and allergic diseases[J]. N Eng I J Med, 2001, 344(1):30-37.
[8]
Van Oosterhout AJ, Motta AC. Th1/Th2 paradigm:not seeing the forest for the trees?[J]. Eur Respir J, 2005, 25(4):591-593.[9] Choi IS. Immune tolerance by induced regulatory T cells in asthma[J]. Allergy Asthma Immunol Res[J]. 2012, 4(3):113-115.
[10]
Veldhoen M, Hocking RJ, Atkins CJ, et a1. TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells[J]. Immunity, 2006, 24(2):179-189.
Temelkovski J, Hogan SP, Shepherd DP, et al. An improved murine model of asthma:selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen[J]. Thorax, 1998, 53(10):849-856.
[14]
陈跃华, 朱华芳, 范婷婷. 哮喘患儿CD4+CD25+ T 细胞Foxp3 表达的意义[J]. 实用儿科临床杂志, 2007, 22(9):657-658.
[15]
Xue K, Zhou Y, Xiong S, et al. Analysis of CD4+ CD25+ regulatory T cells and Foxp3 mRNA in the peripheral blood of patients with asthma[J]. J Huazhong Univ Sci Technolog, 2007, 27(1):31-33.
[16]
Zu Y, Li CR, Zheng YJ, et al. The role of CD4+CD25+ regulatory T cells in the pathogenesis of asthma in children[J]. Zhonghua Yi Xue Za Zhi, 2006, 86(1):35-38.
Jones CE, Chan K. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine[J]. Am J Respir Cell Mol Biol, 2002, 26(6):748-753.
[20]
Oboki K, Ohno T, Saito H, et al. Th17 and allergy[J]. Allergol Int, 2008, 57(2):121-34.
[21]
Barczyk A, Pierzchala W, Sozanska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine[J]. Respir Med, 2003, 97(6):726-733.
[22]
Kearley J, Barker JE, Robinson DS, et al. Resolution of airway inflammation and hyperreactivity after in vivo transfer ofCD4+CD25+ regulatory T cells is interleukin 10 dependent[J]. ExpMed, 2005, 202(11):1539-1547.
[23]
Kearley J, Robinson DS, Lloyd CM. CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling[J]. Allergy Clin Immunol, 2008, 122(3):617-624.
[24]
Lauren EM, Ammon-Treiber S, Mothes B, et al. Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism[J]. J Clin Invest, 2013, 123(3):1216-1228.
[25]
Donaldson DS, Apostolaki M, Bone HK, et al. The Escherichia coli heat-labile enterotoxin B subunit protects from allergic airway disease development by inducing CD4+ regulatory T cells[J]. Mucosal Immunol, 2013, 6(3):535-546.
Bulek K, Caini Liu, Swaidani S, et al. The inducible kinase IKKi is required for interleukin 17-dependent signaling associated with neutrophilia and pulmonary inflammation[J]. Nat Immunol, 2011, 12(9):844-852.
[28]
Molet S, Hamid Q, Davoine F, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines[J]. J Allergy Clin Immunol, 2001, 108(3):430-438.
[29]
Molet SM, Hamid QA, Hamilos DL. IL-11 and IL-17 expression in nasal polyps:relation ship to collagen deposition and suppression by intranasal fluticasone propionate[J]. Laryngoscope, 2003, 113(10):1803-1812.
[30]
Wang Q, Li H, Yao Y, et al. The overexpression of heparinbinding epidermal growth factor is responsible for Th17-induced airway remodeling in an experimental asthma model[J]. J Immunol, 2010, 185(2):834-841.
[31]
Zhao J, Lloyd CM, Noble A. Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling[J]. Mucosal Immunol, 2013, 6(2):335-346.
